Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,067,832
  • Shares Outstanding, K 1,636,700
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.18
  • Price/Sales 5.16
  • Price/Cash Flow 19.94
  • Price/Book 6.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.79 +2.74%
on 10/27/17
64.56 -4.85%
on 10/25/17
-2.22 (-3.49%)
since 10/24/17
3-Month
58.18 +5.59%
on 08/29/17
66.10 -7.07%
on 10/13/17
+3.26 (+5.60%)
since 08/24/17
52-Week
46.01 +33.51%
on 01/26/17
66.10 -7.07%
on 10/13/17
+4.68 (+8.25%)
since 11/23/16

Most Recent Stories

More News
3 Companies Competing to Gain Lead in Ovarian Cancer Market

Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

AZN : 33.84 (+0.03%)
MRK : 54.35 (-0.04%)
CLVS : 60.94 (-0.94%)
ABBV : 94.72 (+0.26%)
TSRO : 83.41 (-0.60%)
PFE : 35.49 (+0.17%)
BMY : 61.43 (+0.47%)
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
NVS : 85.08 (+0.71%)
RHHBY : 31.6000 (-0.19%)
GSK : 35.04 (-0.06%)
BMY : 61.43 (+0.47%)
J&J Seeks Darzalex's Label Expansion in First-Line Setting

Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

CELG : 104.50 (-0.63%)
JNJ : 138.01 (+0.52%)
AMGN : 170.12 (+0.09%)
BMY : 61.43 (+0.47%)
Bristol-Myers Squibb to Take Part in Evercore ISI Biopharma Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI Biopharma Conference on Wednesday, November 29, 2017, in Boston. Fouad Namouni, senior vice president, head...

BMY : 61.43 (+0.47%)
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.

CLDX : 2.90 (+0.35%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
BMY : 61.43 (+0.47%)
With Latest Update, FDA Approval Soon Could Send BTCY Ripping

Response to US FDA Request Met, BTCY Could be Right Around the Corner From an FDA Clearance by Year-End, Likelihood of Approval is High

EKSO : 2.88 (-17.48%)
F : 12.10 (+0.25%)
BTCY : 3.8800 (-9.56%)
BEAT : 25.95 (+1.37%)
IRTC : 57.68 (+0.84%)
NKTR : 52.59 (+5.71%)
BMY : 61.43 (+0.47%)
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

NVS : 85.08 (+0.71%)
RHHBY : 31.6000 (-0.19%)
PFE : 35.49 (+0.17%)
BMY : 61.43 (+0.47%)
US Anticoagulation Therapy Market to 2022 - Major Players are C. H. Boehringer Sohn, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Daiichi Sankyo and Portola Pharmaceuticals

The "US Anticoagulation Therapy Market - Forecast to 2022" report has been added to Research and Markets' offering.

JNJ : 138.01 (+0.52%)
PTLA : 50.55 (-1.40%)
BMY : 61.43 (+0.47%)
LabCorp Reports New Use of Agilent's Cancer Diagnostic Test

The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.

PETS : 38.68 (-3.37%)
ALGN : 254.76 (+0.15%)
LH : 151.09 (-0.54%)
BMY : 61.43 (+0.47%)
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

BAYRY : 32.2200 (+0.53%)
AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
PCRX : 45.95 (+3.26%)
BMY : 61.43 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Key Turning Points

2nd Resistance Point 61.94
1st Resistance Point 61.68
Last Price 61.43
1st Support Level 61.10
2nd Support Level 60.78

See More

52-Week High 66.10
Last Price 61.43
Fibonacci 61.8% 58.43
Fibonacci 50% 56.06
Fibonacci 38.2% 53.68
52-Week Low 46.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart